BRIEF—New strategic collab to focus on inflammatory diseases

Two American firms, Evommune and Accutar Biotechnology, have announced a strategic partnership focused on the discovery of novel small molecules in chronic inflammatory diseases.

Accutar will use its proprietary AI platform, while Evommune will contribute expertise in the design and development of oral medicines.

Evommune chief scientific officer Jeegar Patel said: "Accutar has a highly sophisticated hybrid approach of computational drug design and wet lab validation.”

He added: "Accutar is a team we know well, having collaborated with them on our current program targeting PKCθ, and we are thrilled to be expanding our partnership in a broader capacity."